ࡱ>  l \pThe Free Software Foundation B=PF0*8X@"1 Helvetica1Courier1 Courier New1 Courier New1 Helvetica$#,##0_);($#,##0)$#,##0_);[Red]($#,##0)$#,##0.00_);($#,##0.00)$#,##0.00_);[Red]($#,##0.00)-**_($* #,##0_);_($* (#,##0);_($* "-"_);_(@_)*)'_(* #,##0_);_(* (#,##0);_(* "-"_);_(@_)5,2_($* #,##0.00_);_($* (#,##0.00);_($* "-"??_);_(@_)2+/_(* #,##0.00_);_(* (#,##0.00);_(* "-"??_);_(@_)2$#,##0.00;[Red]$#,##0.003$#,##0.00;[Red]($#,##0.00)4$#,##0;[Red]($#,##00)50.00%;[Red](0.00%)6 0%;[Red](0%)7#,##0.00;[Red](#,##0.00)8#,##0;[Red](#,##0)                + ) , *   Ј ~~ ؈ ~~#؈ ~~ ؈ ~~8#܈ ~~<#܈ ~~4#܈ ~~3#܈ ~~83ffff̙̙3f3fff3f3f33333f33 NxStage Medical Inc Balance Sheet"Balance Sheet (1)IBIncome Statement~h Cash FlowsWarranty Costs&tRecent Accounting PronouncementRecent Accounting (1)&7 Accrued Expenses Other Curren$7 Accrued Expenses Other (1)$7 Accrued Expenses Other (2)9 Segment DisclosuresQ9 Segment Discl (1)&^Stockbased Compensation Expense!14 Noncontrolling Interest&|15 Derivative Instruments and H&!16 Accumulated Other Comprehens!.17 Fair Value Measurements=17 Fair Value M (1)&6J18 Supplemental Cash Flow Infor WFinancial PerformancezoRevenuesGross Profit LossOSelling and Marketing,Research and Development Distribution!General and Administrative&Liquidity and Capital Resources6Item 6 Exhibits l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/?? Balance SheetBalance Sheet (1)Income Statement Cash FlowsWarranty Costs!Recent Accounting PronouncementRecent Accounting (1)!7 Accrued Expenses Other Curren7 Accrued Expenses Other (1)7 Accrued Expenses Other (2)9 Segment Disclosures9 Segment Discl (1)!Stockbased Compensation Expense14 Noncontrolling Interest!15 Derivative Instruments and H!16 Accumulated Other Comprehens17 Fair Value Measurements17 Fair Value M (1)!18 Supplemental Cash Flow InforFinancial Performance RevenuesGross Profit LossSelling and MarketingResearch and Development DistributionGeneral and Administrative!Liquidity and Capital ResourcesItem 6 ExhibitsU } 6} $ } +      NxStage Medical, Inc. 10-Q 11/08/2017NxStage Medical, Inc.    Delaware   04-34547025 -(State or Other Jurisdiction of Incorporation , $(I.R.S. Employer Identification No.) or Organization)   '350 Merrimack St., Lawrence, MA~ 0((Address of Principal Executive Offices) (Zip Code)$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/.th\8qMr=PF0*8X> @ l  & -"  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NxStage Medical IncBalance Sheet (1)Income Statement Cash FlowsWarranty Costs!Recent Accounting PronouncementRecent Accounting (1)!7 Accrued Expenses Other Curren7 Accrued Expenses Other (1)7 Accrued Expenses Other (2)9 Segment Disclosures9 Segment Discl (1)!Stockbased Compensation Expense14 Noncontrolling Interest!15 Derivative Instruments and H!16 Accumulated Other Comprehens17 Fair Value Measurements17 Fair Value M (1)!18 Supplemental Cash Flow InforFinancial Performance RevenuesGross Profit LossSelling and MarketingResearch and Development DistributionGeneral and Administrative!Liquidity and Capital ResourcesItem 6 ExhibitsU } $ } 7}  &     NxStage Medical, Inc. 10-Q 11/08/2017 Balance Sheet      Page& PART I - FINANCIAL INFORMATION 1 )Item 1. Financial Statements (unaudited):  - %Condensed Consolidated Balance Sheets~ 3+at September 30, 2017 and December 31, 2016,$Condensed Consolidated Statements of~ 1)Comprehensive Loss for the Three and Nine0(Months Ended September 30, 2017 and 2016,$Condensed Consolidated Statements of~ 6.Cash Flows for the Nine Months Ended September30, 2017 and 20161)Notes to Condensed Consolidated Financial~ " Statements4,Item 2. Management's Discussion and Analysis~ N80of Financial Condition and Results of Operations80Item 3. Quantitative and Qualitative Disclosures~ nAbout Market Risk'Item 4. Controls and Procedures~ r#PART II - OTHER INFORMATION~ rItem 1A. Risk Factors~ rItem 6. Exhibits~ D6l|pd@VH@R5 !"#$%  SIGNATURES~ !"$#____________________________1$)Created by Morningstar Document Research.0%(http://documentresearch.morningstar.com/Ed=PF0*8X> @r%%$$##    l  D#2>?  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NxStage Medical Inc Balance SheetIncome Statement Cash FlowsWarranty Costs!Recent Accounting PronouncementRecent Accounting (1)!7 Accrued Expenses Other Curren7 Accrued Expenses Other (1)7 Accrued Expenses Other (2)9 Segment Disclosures9 Segment Discl (1)!Stockbased Compensation Expense14 Noncontrolling Interest!15 Derivative Instruments and H!16 Accumulated Other Comprehens17 Fair Value Measurements17 Fair Value M (1)!18 Supplemental Cash Flow InforFinancial Performance RevenuesGross Profit LossSelling and MarketingResearch and Development DistributionGeneral and Administrative!Liquidity and Capital ResourcesItem 6 ExhibitsU } :} $ D     NxStage Medical, Inc. 10-Q 11/08/2017 Balance Sheet           September 30,   December 31, ~  ~  ) !(In thousands, except share data) ASSETS   Current assets:!Cash and cash equivalents~ ~ £ Accounts receivable, net~ ~ z Inventory~ ~ 1)Prepaid expenses and other current assets~ }~ _Total current assets~ E ~ #Property and equipment, net~ ~ Field equipment, net~ s~ \!Deferred cost of revenues~ V~ 6Intangible assets, net~ ~ bGoodwill~ ~ b Other assets~ T~ - Total assets~ ~ ^\,$LIABILITIES AND STOCKHOLDERS? EQUITYCurrent liabilities:Accounts payable~ ~ Accrued expenses~ F~ &)!Current portion of long-term debt~ ~ "D l|pdNtFXT` !"#$%&'()*+,-./0123456789:;<=>?! Other current liabilities~ G  ~ : !!Total current liabilities~ !!!~ !!"Deferred revenues~ """~ ""#Long-term debt~ ###~ #f##$Other long-term liabilities~ $*$$~ $B$%Total liabilities~ %%%~ %%,&$Commitments and contingencies (Notes&&&' 1 and 10)/('Noncontrolling interests subject to put~ (* ((~ (() provisions*Stockholders? equity:***/+'Undesignated preferred stock: par value +?++ +?+,,$$0.001, 5,000,000 shares authorized;8-0no shares issued and outstanding as of September&.30, 2017 and December 31, 20163/+Common stock: par value $0.001, 100,000,000~ ///~ //40,shares authorized; 67,231,121 and 65,883,02621*shares issued as of September 30, 2017 and'2December 31, 2016, respectively"3Additional paid-in capital~ 3'33~ 3Ά&34Accumulated deficit~ 4h44~ 4>4,5$Accumulated other comprehensive loss~ 5f55~ 55.6&Treasury stock, at cost: 1,034,188 and~ 666~ 6"6/7'936,360 shares as of September 30, 2017+8#and December 31, 2016, respectively19)Total NxStage Medical, Inc. stockholders'~ 92 99~ 9J 9:equity,;$Noncontrolling interests not subject~ ;;;~ ; ;<to put provisions"=Total stockholders' equity~ = ==~ =T =2>*Total liabilities and stockholders? equity~ >>>~ >^\>?D l6gR}m8dmP@ABC@$A____________________________1B)Created by Morningstar Document Research.0C(http://documentresearch.morningstar.com/ <=PF0*8X> @BHCCBBAA>>>>====;;;;99996666555544443333////++++((((%%%%$$$$####""""!!!!        l  8nWUd  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NxStage Medical Inc Balance SheetBalance Sheet (1) Cash FlowsWarranty Costs!Recent Accounting PronouncementRecent Accounting (1)!7 Accrued Expenses Other Curren7 Accrued Expenses Other (1)7 Accrued Expenses Other (2)9 Segment Disclosures9 Segment Discl (1)!Stockbased Compensation Expense14 Noncontrolling Interest!15 Derivative Instruments and H!16 Accumulated Other Comprehens17 Fair Value Measurements17 Fair Value M (1)!18 Supplemental Cash Flow InforFinancial Performance RevenuesGross Profit LossSelling and MarketingResearch and Development DistributionGeneral and Administrative!Liquidity and Capital ResourcesItem 6 ExhibitsU } >} $ } $} $ 8     NxStage Medical, Inc. 10-Q 11/08/2017Income Statement                 (  Three Months Ended September 30, ' Nine Months Ended September 30, ~  ~  ~  ~  - %(In thousands, except per share data) Revenues~ >  ~   ~   ~ V Cost of revenues~ u~ 8~  F7   ~  2  Gross profit~ ~z~ 6d~  N  ~  &Operating expenses:   Selling and marketing~ b ~ b~    ~   Research and development~ Z~ Z~    ~  m Distribution~ ~~ ^n~  m  ~  .J"General and administrative~ .~ y~    ~  :| Total operating expenses~ ~ c~  =  ~  r%(Loss) income from operations~ ~~ b~  2D  ~  Other expense:   Interest expense, net~ b~ 2~    ~  #Other income (expense), net~ j~ ~  .  ~  ~ ~ ~    ~  $Net loss before income taxes~ ^|~ *~  2  ~  62*Provision for (benefit fro m) income taxes~ V~ ~  j  ~  Net loss~  u~ ~  4  ~  z5-Less: Net loss attributable to noncontrolling~ ~ ~    ~   interestsDlyma2E.-{H: !"#$%&'()*+,-./012345671 )Net loss attributable to NxStage Medical,~ |  ~ j  ~ H  ~ j  !Inc.<"4Add: Accretion to redemption value of noncontrolling~ "~"" "?""~ " ~" "  " ?"# interests4$,Net loss attributable to common stockholders~ $t$$~ $j$$~ $ RA$ $ ~ $ j$%%%%%% % % -&%Net loss per share, basic and diluted&Q&&~ & &)&& RQȿ& & & &,'$Weighted-average shares outstanding,~ '''~ '''~ ' ' ' ~ ' z'(basic and diluted)))))) ) ) **"Other comprehensive (loss) income:***** * * .+&Unrealized (loss) income on derivative~ +++~ +++~ + "%+ + ~ + r+(, instruments, net of income taxes-Other income (loss)~ -2--~ ---~ - - - ~ - -/.'Total other comprehensive (loss) income~ ...~ ...~ . A. . ~ . ^. /Total comprehensive loss~ /n//~ ///~ / bv/ / ~ / ֮/-0%Less: Comprehensive loss attributable~ 000~ 000~ 0 0 0 ~ 0 0#1to noncontrolling interests-2%Total comprehensive loss attributable~ 2u22~ 2222~ 2 2 2 ~ 2 2 3to NxStage Medical, Inc.4$5____________________________16)Created by Morningstar Document Research.07(http://documentresearch.morningstar.com/4 ?/eP,b)S=PF0*8X> @v776655222222 22 000000 00 ////// // ...... .. ------ -- ++++++ ++ '''''' '' &&&&&& && $$$$$$ $$ """""" ""                                            l  7wz  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NxStage Medical Inc Balance SheetBalance Sheet (1)Income StatementWarranty Costs!Recent Accounting PronouncementRecent Accounting (1)!7 Accrued Expenses Other Curren7 Accrued Expenses Other (1)7 Accrued Expenses Other (2)9 Segment Disclosures9 Segment Discl (1)!Stockbased Compensation Expense14 Noncontrolling Interest!15 Derivative Instruments and H!16 Accumulated Other Comprehens17 Fair Value Measurements17 Fair Value M (1)!18 Supplemental Cash Flow InforFinancial Performance RevenuesGross Profit LossSelling and MarketingResearch and Development DistributionGeneral and Administrative!Liquidity and Capital ResourcesItem 6 ExhibitsU } U5} $ 7     NxStage Medical, Inc. 10-Q 11/08/2017 Cash Flows         ' Nine Months Ended September 30, ~  ~   (In thousands)- %Cash flows from operating activities:   Net loss~ 4~ z0(Adjustments to reconcile net loss to net,$cash flow from operating activities:%Depreciation and amortization~ ~ v Stock-based compensation~ ~ "x Other~ ~~ *4,Changes in operating assets and liabilities:Accounts receivable~ .&~  Inventory~ Z~ ڧ)!Prepaid expenses and other assets~ r ~  Accounts payable~ ~ j=.&Accrued expenses and other liabilities~ ~ /Deferred revenues~ :~ 1)Net cash provided by operating activities~ ~ N-%Cash flows from investing activities:/'Cash paid for acquisitions, net of cash~ r~ acquired*"Purchase of cost method investment~  ?D lsgv!uEx'lN B !"#$%&'()*+,-./0123456+ #Purchases of property and equipment~    ~ ҕ .!&Net cash used in investing activities~ !ja!!~ !΍!-"%Cash flows from financing activities:"""0#(Issuance of shares under stock incentive~ #.##~ #v9#($ plans, net of payroll taxes paid-%%Investment by noncontrolling interest %?%%~ %%&holder0'(Proceeds from loans, lines of credit and~ ''' '?'!(capital lease obligations/)'Repayments on loans and lines of credit~ ) ))~ )~)$*Repayments on capital leases~ ***~ **1+)Net cash provided by financing activities~ +++~ +6+0,(Foreign exchange effect on cash and cash~ ,,,~ ,,- equivalents-.%Increase in cash and cash equivalents~ .N4..~ .b.//'Cash and cash equivalents, beginning of~ /£//~ //0period01(Cash and cash equivalents, end of period~ 111~ 1F123$4____________________________15)Created by Morningstar Document Research.06(http://documentresearch.morningstar.com/2V*55L5Q?=PF0*8X> @96655441111////....,,,,++++****))))''''%%%%####!!!!       l  ͊  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NxStage Medical Inc Balance SheetBalance Sheet (1)Income Statement Cash Flows!Recent Accounting PronouncementRecent Accounting (1)!7 Accrued Expenses Other Curren7 Accrued Expenses Other (1)7 Accrued Expenses Other (2)9 Segment Disclosures9 Segment Discl (1)!Stockbased Compensation Expense14 Noncontrolling Interest!15 Derivative Instruments and H!16 Accumulated Other Comprehens17 Fair Value Measurements17 Fair Value M (1)!18 Supplemental Cash Flow InforFinancial Performance RevenuesGross Profit LossSelling and MarketingResearch and Development DistributionGeneral and Administrative!Liquidity and Capital ResourcesItem 6 ExhibitsU } y#} $      NxStage Medical, Inc. 10-Q 11/08/2017Warranty Costs    $ Balance at December 31, 2016~ b   Provision~   Usage~  % Balance at September 30, 2017~ 6 $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/*h{oc3TH<=PF0*8X> @:     l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NxStage Medical Inc Balance SheetBalance Sheet (1)Income Statement Cash FlowsWarranty CostsRecent Accounting (1)!7 Accrued Expenses Other Curren7 Accrued Expenses Other (1)7 Accrued Expenses Other (2)9 Segment Disclosures9 Segment Discl (1)!Stockbased Compensation Expense14 Noncontrolling Interest!15 Derivative Instruments and H!16 Accumulated Other Comprehens17 Fair Value Measurements17 Fair Value M (1)!18 Supplemental Cash Flow InforFinancial Performance RevenuesGross Profit LossSelling and MarketingResearch and Development DistributionGeneral and Administrative!Liquidity and Capital ResourcesItem 6 ExhibitsU } } $      NxStage Medical, Inc. 10-Q 11/08/201780Recent Accounting Pronouncements Not Yet Adopted           September 30,   December 31, ~  ~  Purchased components~ 6  ~   Work in process~   ~  Finished goods~ F~ N Total~ ~ $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/.OqeYMAdO=PF0*8X> @z         l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NxStage Medical Inc Balance SheetBalance Sheet (1)Income Statement Cash FlowsWarranty Costs!Recent Accounting Pronouncement!7 Accrued Expenses Other Curren7 Accrued Expenses Other (1)7 Accrued Expenses Other (2)9 Segment Disclosures9 Segment Discl (1)!Stockbased Compensation Expense14 Noncontrolling Interest!15 Derivative Instruments and H!16 Accumulated Other Comprehens17 Fair Value Measurements17 Fair Value M (1)!18 Supplemental Cash Flow InforFinancial Performance RevenuesGross Profit LossSelling and MarketingResearch and Development DistributionGeneral and Administrative!Liquidity and Capital ResourcesItem 6 ExhibitsU } '}  } $ }  } $ }  }  $ } U} $                      NxStage Medical, Inc. 10-Q 11/08/201780Recent Accounting Pronouncements Not Yet Adopted             (  Three Months Ended September 30, ' Nine Months Ended September 30, ~  ~  ~  ~ (  Options to purchase common stock~   ~ "  ~   ~   ! Unvested restricted stock~   ~   ~   ~   Total~ ~ ~ R ~  F $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,j|qeYMAB"q=PF0*8X> @J         l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NxStage Medical Inc Balance SheetBalance Sheet (1)Income Statement Cash FlowsWarranty Costs!Recent Accounting PronouncementRecent Accounting (1)7 Accrued Expenses Other (1)7 Accrued Expenses Other (2)9 Segment Disclosures9 Segment Discl (1)!Stockbased Compensation Expense14 Noncontrolling Interest!15 Derivative Instruments and H!16 Accumulated Other Comprehens17 Fair Value Measurements17 Fair Value M (1)!18 Supplemental Cash Flow InforFinancial Performance RevenuesGross Profit LossSelling and MarketingResearch and Development DistributionGeneral and Administrative!Liquidity and Capital ResourcesItem 6 ExhibitsU } 2} $      NxStage Medical, Inc. 10-Q 11/08/2017VN7. Accrued Expenses, Other Current Liabilities and Other Long-Term Liabilities           September 30,   December 31, ~  ~ 2 *Payroll, compensation and related benefits~ v  ~   Distribution expenses~ 2P  ~ K +#General and administrative expenses~ ~ D( Audit, legal and consulting fees~ 66~ v!Other manufacturing costs~ &~  Other~ ?~ E Total~ F~ &$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/4SG;/#zFo/|pH=PF0*8X> @         l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NxStage Medical Inc Balance SheetBalance Sheet (1)Income Statement Cash FlowsWarranty Costs!Recent Accounting PronouncementRecent Accounting (1)!7 Accrued Expenses Other Curren7 Accrued Expenses Other (2)9 Segment Disclosures9 Segment Discl (1)!Stockbased Compensation Expense14 Noncontrolling Interest!15 Derivative Instruments and H!16 Accumulated Other Comprehens17 Fair Value Measurements17 Fair Value M (1)!18 Supplemental Cash Flow InforFinancial Performance RevenuesGross Profit LossSelling and MarketingResearch and Development DistributionGeneral and Administrative!Liquidity and Capital ResourcesItem 6 ExhibitsU } <(} $      NxStage Medical, Inc. 10-Q 11/08/2017VN7. Accrued Expenses, Other Current Liabilities and Other Long-Term Liabilities           September 30,   December 31, ~  ~ ! Capital lease obligations~ !  ~  ) !Deferred revenue, current portion~   ~ .  Other~ j~   Total~ G~ :$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/.{SG;/#zFt#=PF0*8X> @z         l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NxStage Medical Inc Balance SheetBalance Sheet (1)Income Statement Cash FlowsWarranty Costs!Recent Accounting PronouncementRecent Accounting (1)!7 Accrued Expenses Other Curren7 Accrued Expenses Other (1)9 Segment Disclosures9 Segment Discl (1)!Stockbased Compensation Expense14 Noncontrolling Interest!15 Derivative Instruments and H!16 Accumulated Other Comprehens17 Fair Value Measurements17 Fair Value M (1)!18 Supplemental Cash Flow InforFinancial Performance RevenuesGross Profit LossSelling and MarketingResearch and Development DistributionGeneral and Administrative!Liquidity and Capital ResourcesItem 6 ExhibitsU } !} $      NxStage Medical, Inc. 10-Q 11/08/2017VN7. Accrued Expenses, Other Current Liabilities and Other Long-Term Liabilities           September 30,   December 31, ~  ~ ! Capital lease obligations~ .  ~  # Lease incentive obligations~ j,  ~ /  Benefit plan obligations~ ~ : Other~ ~ "  Total~ *~ B$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/0SG;/#zFzocW/=PF0*8X> @         l  (y  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NxStage Medical Inc Balance SheetBalance Sheet (1)Income Statement Cash FlowsWarranty Costs!Recent Accounting PronouncementRecent Accounting (1)!7 Accrued Expenses Other Curren7 Accrued Expenses Other (1)7 Accrued Expenses Other (2)9 Segment Discl (1)!Stockbased Compensation Expense14 Noncontrolling Interest!15 Derivative Instruments and H!16 Accumulated Other Comprehens17 Fair Value Measurements17 Fair Value M (1)!18 Supplemental Cash Flow InforFinancial Performance RevenuesGross Profit LossSelling and MarketingResearch and Development DistributionGeneral and Administrative!Liquidity and Capital ResourcesItem 6 ExhibitsU } -} $ (     NxStage Medical, Inc. 10-Q 11/08/20179. Segment Disclosures                           System One   In-Center  Other  Services  Intersegment Elimination  Total- %Three Months Ended September 30, 2017           (  Revenues from external customers~ |  ~   ~ 5  ~ ~M   $?  ~ >  Intersegment revenues~    ?   ?   ?  ~ N   ? Revenues~ Ҏ~ ~  5  ~  ~M~ N~ >Segment profit (loss)~ %~ N!~  :  ~  ~ >~ ~%Depreciation and amortization~ V~ ~    ~  ~ ~ -%Three Months Ended September 30, 2016   ( Revenues from external customers~ E~ v~  F8  ~  < $?~ Intersegment revenues~ * ?  ?    ?~  ?Revenues~ d~ v~  F8  ~  <~ ~ Segment profit (loss)~ 5~ ~&~     ~  B~ ~ b%Depreciation and amortization~ ]~ ~    ~  B~ R~ ,$Nine Months Ended September 30, 2017   ( Revenues from external customers~ Z| ~ V~    ~  J $?~ Intersegment revenues~ < ?  ?    ?~  ?Revenues~ n ~ V~    ~  J~ ~ Segment profit (loss)~ ֩~ "`~  O  ~  ~ ~ 2D%Depreciation and amortization~ f~ ~  2  ~  <~ .~ ,$Nine Months Ended September 30, 2016   ( Revenues from external customers~  ~ ~    ~  ^ $?~ VIntersegment revenues~ V ?  ?    ?~ > ?Dzlsg[;n%!,@GF !"#$%&' Revenues~ N   ~   ~   ~ ^  ~ >  ~ V !Segment profit (loss)~ !j!!~ !n!!~ ! ,! ! ~ ! !!~ !!!~ !!%"Depreciation and amortization~ "J""~ "F""~ " 4" " ~ " 5""~ """~ "v"#$$%____________________________1&)Created by Morningstar Document Research.0'(http://documentresearch.morningstar.com//=PF0*8X> @ ''&&%%"""""" "" """"!!!!!! !! !!!!                                                   l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NxStage Medical Inc Balance SheetBalance Sheet (1)Income Statement Cash FlowsWarranty Costs!Recent Accounting PronouncementRecent Accounting (1)!7 Accrued Expenses Other Curren7 Accrued Expenses Other (1)7 Accrued Expenses Other (2)9 Segment Disclosures!Stockbased Compensation Expense14 Noncontrolling Interest!15 Derivative Instruments and H!16 Accumulated Other Comprehens17 Fair Value Measurements17 Fair Value M (1)!18 Supplemental Cash Flow InforFinancial Performance RevenuesGross Profit LossSelling and MarketingResearch and Development DistributionGeneral and Administrative!Liquidity and Capital ResourcesItem 6 ExhibitsU } } $} $} $ } $} $} $ } $} $} $ } $} $                     NxStage Medical, Inc. 10-Q 11/08/20179. Segment Disclosures             (  Three Months Ended September 30, ' Nine Months Ended September 30, ~  ~  ~  ~  DaVita~ R % ~ V % ~ R % ~ R %  Fresenius~ R % ~ J % ~ N % ~ J %$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/*xhsg[\Rm=PF0*8X> @J         l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NxStage Medical Inc Balance SheetBalance Sheet (1)Income Statement Cash FlowsWarranty Costs!Recent Accounting PronouncementRecent Accounting (1)!7 Accrued Expenses Other Curren7 Accrued Expenses Other (1)7 Accrued Expenses Other (2)9 Segment Disclosures9 Segment Discl (1)14 Noncontrolling Interest!15 Derivative Instruments and H!16 Accumulated Other Comprehens17 Fair Value Measurements17 Fair Value M (1)!18 Supplemental Cash Flow InforFinancial Performance RevenuesGross Profit LossSelling and MarketingResearch and Development DistributionGeneral and Administrative!Liquidity and Capital ResourcesItem 6 ExhibitsU } } $      NxStage Medical, Inc. 10-Q 11/08/2017( Stock-based Compensation Expense                 (  Three Months Ended September 30, ' Nine Months Ended September 30, ~  ~  ~  ~  Cost of revenues~ >  ~   ~   ~   Selling and marketing~ z  ~ 6   ~ /  ~  (  Research and development~ ~ b~     ~  "General and administrative~ ~ ^ ~  7  ~  - Total~ 4~ #~    ~  "x$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/0ui]Q"efZN&=PF0*8X> @                  l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NxStage Medical Inc Balance SheetBalance Sheet (1)Income Statement Cash FlowsWarranty Costs!Recent Accounting PronouncementRecent Accounting (1)!7 Accrued Expenses Other Curren7 Accrued Expenses Other (1)7 Accrued Expenses Other (2)9 Segment Disclosures9 Segment Discl (1)!Stockbased Compensation Expense!15 Derivative Instruments and H!16 Accumulated Other Comprehens17 Fair Value Measurements17 Fair Value M (1)!18 Supplemental Cash Flow InforFinancial Performance RevenuesGross Profit LossSelling and MarketingResearch and Development DistributionGeneral and Administrative!Liquidity and Capital ResourcesItem 6 ExhibitsU } 8} $      NxStage Medical, Inc. 10-Q 11/08/2017#14. Noncontrolling Interest                 (  Three Months Ended September 30, ' Nine Months Ended September 30, ~  ~  ~  ~ & Balance at beginning of period~   ~   ~    ~ z / 'Capital contributions by noncontrolling ?  ~    ?  ~ N interest)!Sales of noncontrolling interests ? ?  ?  ~   7/Accretion to redemption value of noncontrolling~  ?~      ? interests3+Reclassification of noncontrolling interest~ b ?~  b    ? subject to put provision/'Net loss attributable to noncontrolling~ "~ ~    ~  +#interest in consolidated subsidiary Balance at end of period~ ~ ~    ~  $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/< znbV' L8% =PF0*8X> @*%                      l     dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NxStage Medical Inc Balance SheetBalance Sheet (1)Income Statement Cash FlowsWarranty Costs!Recent Accounting PronouncementRecent Accounting (1)!7 Accrued Expenses Other Curren7 Accrued Expenses Other (1)7 Accrued Expenses Other (2)9 Segment Disclosures9 Segment Discl (1)!Stockbased Compensation Expense14 Noncontrolling Interest!16 Accumulated Other Comprehens17 Fair Value Measurements17 Fair Value M (1)!18 Supplemental Cash Flow InforFinancial Performance RevenuesGross Profit LossSelling and MarketingResearch and Development DistributionGeneral and Administrative!Liquidity and Capital ResourcesItem 6 ExhibitsU } -}  $ } :                            NxStage Medical, Inc. 10-Q 11/08/2017.&15. Derivative Instruments and Hedging             % Gain (Loss) Recognized in OCI . &Gain (Loss) Reclassified from OCI into 8 0Classification within the Condensed Consolidated   (Effective Portion)  Income ' Statement of Comprehensive Loss       (Effective Portion)- %Three Months Ended September 30, 2017      *"Foreign exchange forward contracts~ ~ v   Cost of revenues,$Nine Months Ended September 30, 2017  *"Foreign exchange forward contracts~ A~   Cost of revenues-%Three Months Ended September 30, 2016  *"Foreign exchange forward contracts~ ~   Cost of revenues,$Nine Months Ended September 30, 2016  *"Foreign exchange forward contracts~ ~   Cost of revenues$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/8 {ocWKt z_Ec=PF0*8X> @         l  -  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NxStage Medical Inc Balance SheetBalance Sheet (1)Income Statement Cash FlowsWarranty Costs!Recent Accounting PronouncementRecent Accounting (1)!7 Accrued Expenses Other Curren7 Accrued Expenses Other (1)7 Accrued Expenses Other (2)9 Segment Disclosures9 Segment Discl (1)!Stockbased Compensation Expense14 Noncontrolling Interest!15 Derivative Instruments and H17 Fair Value Measurements17 Fair Value M (1)!18 Supplemental Cash Flow InforFinancial Performance RevenuesGross Profit LossSelling and MarketingResearch and Development DistributionGeneral and Administrative!Liquidity and Capital ResourcesItem 6 ExhibitsU } >}  $                         NxStage Medical, Inc. 10-Q 11/08/20179116. Accumulated Other Comprehensive (Loss) Income               1 )Unrealized gain on derivative instruments   Other (2)  Total4 ,Balance, net of tax, as of December 31, 2016 ~ N  ~ b  ~  < 4Other comprehensive income before reclassifications, ~ )  ~   ~ E % net of $1,581 tax during 2017)!Gain reclassified to earnings (1)~   ? ~    -%Total other comprehensive income, net~ "%~  ~  A of tax0(Balance, net of tax, as of September 30,~ n~  ~  f ~ $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/2pdXL@oSAY=PF0*8X> @            l  ;  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NxStage Medical Inc Balance SheetBalance Sheet (1)Income Statement Cash FlowsWarranty Costs!Recent Accounting PronouncementRecent Accounting (1)!7 Accrued Expenses Other Curren7 Accrued Expenses Other (1)7 Accrued Expenses Other (2)9 Segment Disclosures9 Segment Discl (1)!Stockbased Compensation Expense14 Noncontrolling Interest!15 Derivative Instruments and H!16 Accumulated Other Comprehens17 Fair Value M (1)!18 Supplemental Cash Flow InforFinancial Performance RevenuesGross Profit LossSelling and MarketingResearch and Development DistributionGeneral and Administrative!Liquidity and Capital ResourcesItem 6 ExhibitsU } 0.} $      NxStage Medical, Inc. 10-Q 11/08/2017#17. Fair Value Measurements                  September 30, 2017 5 -Quoted Prices in Active Markets for Identical + #Significant Other Observable Inputs ' Significant Unobservable Inputs  Total Fair Value   Assets   (Level 2)   (Level 3)    (Level 1) Assets        Money market funds (1)~ " $?   $?  ~ ".&Foreign exchange forward contracts (2) ?~     ?  ~   Liabilities   .&Foreign exchange forward contracts (2) $?~ .   $?  ~ .$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/2znbV!=PF0*8X> @          l  )I  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NxStage Medical Inc Balance SheetBalance Sheet (1)Income Statement Cash FlowsWarranty Costs!Recent Accounting PronouncementRecent Accounting (1)!7 Accrued Expenses Other Curren7 Accrued Expenses Other (1)7 Accrued Expenses Other (2)9 Segment Disclosures9 Segment Discl (1)!Stockbased Compensation Expense14 Noncontrolling Interest!15 Derivative Instruments and H!16 Accumulated Other Comprehens17 Fair Value Measurements!18 Supplemental Cash Flow InforFinancial Performance RevenuesGross Profit LossSelling and MarketingResearch and Development DistributionGeneral and Administrative!Liquidity and Capital ResourcesItem 6 ExhibitsU } 0.} $      NxStage Medical, Inc. 10-Q 11/08/2017#17. Fair Value Measurements                  December 31, 2016 5 -Quoted Prices in Active Markets for Identical + #Significant Other Observable Inputs ' Significant Unobservable Inputs  Total Fair Value   Assets   (Level 2)   (Level 3)    (Level 1) Assets        Money market funds (1)~  $?   $?  ~  Liabilities   .&Foreign exchange forward contracts (2) $?~    $?  ~ $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/0znbV"R|pH=PF0*8X> @         l  U  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NxStage Medical Inc Balance SheetBalance Sheet (1)Income Statement Cash FlowsWarranty Costs!Recent Accounting PronouncementRecent Accounting (1)!7 Accrued Expenses Other Curren7 Accrued Expenses Other (1)7 Accrued Expenses Other (2)9 Segment Disclosures9 Segment Discl (1)!Stockbased Compensation Expense14 Noncontrolling Interest!15 Derivative Instruments and H!16 Accumulated Other Comprehens17 Fair Value Measurements17 Fair Value M (1)Financial Performance RevenuesGross Profit LossSelling and MarketingResearch and Development DistributionGeneral and Administrative!Liquidity and Capital ResourcesItem 6 ExhibitsU } $4} $      NxStage Medical, Inc. 10-Q 11/08/2017.&18. Supplemental Cash Flow Information         ' Nine Months Ended September 30, ~  ~ 3 +Noncash Investing and Financing Activities:   3 +Transfers from inventory to field equipment~ 6  ~  2*Transfers from field equipment to deferred~ Jv~ rcost of revenues2*Market value of shares received in payment~ N+~ %for exercise of stock options-%Redemption of noncontrolling interest~  ?/'PP&E financed by construction liability~ ~ -%Property and equipment acquired under ?~  capital lease$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/8{ocWK%8} *=PF0*8X> @      l  $k!m  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NxStage Medical Inc Balance SheetBalance Sheet (1)Income Statement Cash FlowsWarranty Costs!Recent Accounting PronouncementRecent Accounting (1)!7 Accrued Expenses Other Curren7 Accrued Expenses Other (1)7 Accrued Expenses Other (2)9 Segment Disclosures9 Segment Discl (1)!Stockbased Compensation Expense14 Noncontrolling Interest!15 Derivative Instruments and H!16 Accumulated Other Comprehens17 Fair Value Measurements17 Fair Value M (1)!18 Supplemental Cash Flow Infor RevenuesGross Profit LossSelling and MarketingResearch and Development DistributionGeneral and Administrative!Liquidity and Capital ResourcesItem 6 ExhibitsU } 0} $ } $} $ } $}  $ } $} $ } $ $     NxStage Medical, Inc. 10-Q 11/08/2017Financial Performance                 (  Three Months Ended September 30, ' Nine Months Ended September 30, ~  ~  ~  ~ . &Products Business (System One Segment,       " In-Center Segment & Other)Revenues~ v~ ~~  ^   ~  _ Gross profit~ ~ ~  -  ~  Gross margin percentage~  %~  %~    % ~   %%(Loss) income from operations~ B~ ^g~  Y  ~  rServices Segment   Revenues~ ~M~ <~  J  ~  ^ Gross profit~ ~ v~  T  ~  AGross margin percentage n/a n/a  n/a    n/aLoss from operations~ ~ B~    ~   Eliminations   ,$Elimination of intersegment revenues~ N~ ~    ~  >0(Elimination of intersegment gross profit~ >~ ~    ~   Total Company   Revenues~ >~ ~    ~  V Gross profit~ ~z~ 6d~  N  ~  &Gross margin percentage~  %~  %~    % ~   %%(Loss) income from operations~ ~~ b~  2D  ~  D3lth\-?y"m]Z2re !"# $!____________________________1")Created by Morningstar Document Research.0#(http://documentresearch.morningstar.com/ <=PF0*8X> @ A##""!!                                  l  *  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NxStage Medical Inc Balance SheetBalance Sheet (1)Income Statement Cash FlowsWarranty Costs!Recent Accounting PronouncementRecent Accounting (1)!7 Accrued Expenses Other Curren7 Accrued Expenses Other (1)7 Accrued Expenses Other (2)9 Segment Disclosures9 Segment Discl (1)!Stockbased Compensation Expense14 Noncontrolling Interest!15 Derivative Instruments and H!16 Accumulated Other Comprehens17 Fair Value Measurements17 Fair Value M (1)!18 Supplemental Cash Flow InforFinancial PerformanceGross Profit LossSelling and MarketingResearch and Development DistributionGeneral and Administrative!Liquidity and Capital ResourcesItem 6 ExhibitsU } +} $ } $} $}  $ } $} $} $ } $} $} $ } $} $      NxStage Medical, Inc. 10-Q 11/08/2017Revenues                             (  Three Months Ended September 30, ' Nine Months Ended September 30, ~  ~  ~  ~  System One segment                Home~ h  ~  % ~ G  ~  % ~    ~  % ~ vl   ~  % Critical Care~ "&~ R %~   ~  R  %~ z~ R %~ u~ V % Total System One segment~ Ҏ~ 6 %~ d  ~  :  %~ n ~ 6 %~ N ~ 6 %In-Center segment~ ~ B %~ v  ~  B  %~ V~ B %~ ~ J % Other~ 5~  %~ F8  ~    %~ ~  %~ ~  %Products subtotal~ v~  %~ ~  ~    %~ ^ ~  %~ _~  %Services segment~ ~M~  %~ <  ~    %~ J~  %~ ^~  %,$Elimination of intersegment revenues~ N~  %~   ~    %~ ~  %~ >~  % Total~ >~  %~   ~    %~ ~  %~ V~  %$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/:uiBp8f-L=PF0*8X> @j-                   l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NxStage Medical Inc Balance SheetBalance Sheet (1)Income Statement Cash FlowsWarranty Costs!Recent Accounting PronouncementRecent Accounting (1)!7 Accrued Expenses Other Curren7 Accrued Expenses Other (1)7 Accrued Expenses Other (2)9 Segment Disclosures9 Segment Discl (1)!Stockbased Compensation Expense14 Noncontrolling Interest!15 Derivative Instruments and H!16 Accumulated Other Comprehens17 Fair Value Measurements17 Fair Value M (1)!18 Supplemental Cash Flow InforFinancial Performance RevenuesSelling and MarketingResearch and Development DistributionGeneral and Administrative!Liquidity and Capital ResourcesItem 6 ExhibitsU } 0} $ } $} $}  $ } $} $} $ } $} $} $ } $} $      NxStage Medical, Inc. 10-Q 11/08/2017Gross Profit (Loss)                             (  Three Months Ended September 30, ' Nine Months Ended September 30, ~  ~  ~  ~  System One segment~ k  ~  % ~ b\  ~  % ~ \  ~  % ~   ~  % In-Center segment~ E  ~ v % ~ vD  ~ z % ~ V  ~ r % ~   ~ v %Subtotal~ ~  %~ ֠  ~    %~ $~  %~ ֨~  % Other~ ~  %~ *  ~  .  %~ ~  %~ ~ > %Products subtotal~ ~  %~   ~    %~ -~  %~ ~  %Services segment~  n/a~ v    n/a ~ T n/a~ A n/a0(Elimination of intersegment gross profit~ > n/a~     n/a ~  n/a~  n/a Gross profit~ ~z~  %~ 6d  ~    %~ N~  %~ &~  %$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/6vj^7p7R=PF0*8X> @J)                     l  Ϯ  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NxStage Medical Inc Balance SheetBalance Sheet (1)Income Statement Cash FlowsWarranty Costs!Recent Accounting PronouncementRecent Accounting (1)!7 Accrued Expenses Other Curren7 Accrued Expenses Other (1)7 Accrued Expenses Other (2)9 Segment Disclosures9 Segment Discl (1)!Stockbased Compensation Expense14 Noncontrolling Interest!15 Derivative Instruments and H!16 Accumulated Other Comprehens17 Fair Value Measurements17 Fair Value M (1)!18 Supplemental Cash Flow InforFinancial Performance RevenuesGross Profit LossResearch and Development DistributionGeneral and Administrative!Liquidity and Capital ResourcesItem 6 ExhibitsU } '} $ } $} $}  $ } $} $} $ } $} $} $ } $} $      NxStage Medical, Inc. 10-Q 11/08/2017Selling and Marketing                             (  Three Months Ended September 30, ' Nine Months Ended September 30, ~  ~  ~  ~  System One segment~   ~ J % ~ R  ~ F % ~ ~V  ~ F % ~ R,  ~ F % In-Center segment~   ~ 2 % ~   ~ . % ~ W  ~ 2 % ~ G  ~ * %Products subtotal~ ~ B %~ .  ~  >  %~ ~ B %~ Jt~ > %Services segment~ v n/a~ 6$    n/a ~ i n/a~ Bp n/a( Total Selling and marketing~ b ~ F %~ b  ~  F  %~ ~ F %~ ~ F %$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/0 th\ 5e!=PF0*8X> @                  l  @  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NxStage Medical Inc Balance SheetBalance Sheet (1)Income Statement Cash FlowsWarranty Costs!Recent Accounting PronouncementRecent Accounting (1)!7 Accrued Expenses Other Curren7 Accrued Expenses Other (1)7 Accrued Expenses Other (2)9 Segment Disclosures9 Segment Discl (1)!Stockbased Compensation Expense14 Noncontrolling Interest!15 Derivative Instruments and H!16 Accumulated Other Comprehens17 Fair Value Measurements17 Fair Value M (1)!18 Supplemental Cash Flow InforFinancial Performance RevenuesGross Profit LossSelling and Marketing DistributionGeneral and Administrative!Liquidity and Capital ResourcesItem 6 ExhibitsU } } $ } $} $}  $ } } $} $ } $} $} $ } } $      NxStage Medical, Inc. 10-Q 11/08/2017 Research and Development                             (  Three Months Ended September 30, ' Nine Months Ended September 30, ~  ~  ~  ~  Research and development~ Z  ~ 2 % ~ Z  ~ & % ~   ~ * % ~ m  ~ & % $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/(+T}qeY 2=PF0*8X> @j            l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NxStage Medical Inc Balance SheetBalance Sheet (1)Income Statement Cash FlowsWarranty Costs!Recent Accounting PronouncementRecent Accounting (1)!7 Accrued Expenses Other Curren7 Accrued Expenses Other (1)7 Accrued Expenses Other (2)9 Segment Disclosures9 Segment Discl (1)!Stockbased Compensation Expense14 Noncontrolling Interest!15 Derivative Instruments and H!16 Accumulated Other Comprehens17 Fair Value Measurements17 Fair Value M (1)!18 Supplemental Cash Flow InforFinancial Performance RevenuesGross Profit LossSelling and MarketingResearch and DevelopmentGeneral and Administrative!Liquidity and Capital ResourcesItem 6 ExhibitsU } U} $ } $} $}  $ } } $} $ } $} $} $ } } $      NxStage Medical, Inc. 10-Q 11/08/2017 Distribution                             (  Three Months Ended September 30, ' Nine Months Ended September 30, ~  ~  ~  ~  System One segment~ x  ~ * % ~ Bh  ~ & % ~ Z\  ~ * % ~ 5  ~ & % In-Center segment~   ~   % ~   ~  % ~ 2  ~   % ~ f  ~  % Total Distribution~ ~~ " %~ ^n  ~  "  %~ m~ " %~ .J~ " %$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,|}qe>h\P(=PF0*8X> @                l     dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NxStage Medical Inc Balance SheetBalance Sheet (1)Income Statement Cash FlowsWarranty Costs!Recent Accounting PronouncementRecent Accounting (1)!7 Accrued Expenses Other Curren7 Accrued Expenses Other (1)7 Accrued Expenses Other (2)9 Segment Disclosures9 Segment Discl (1)!Stockbased Compensation Expense14 Noncontrolling Interest!15 Derivative Instruments and H!16 Accumulated Other Comprehens17 Fair Value Measurements17 Fair Value M (1)!18 Supplemental Cash Flow InforFinancial Performance RevenuesGross Profit LossSelling and MarketingResearch and Development Distribution!Liquidity and Capital ResourcesItem 6 ExhibitsU } } $ } $} $}  $ } } $} $ } $} $} $ } } $      NxStage Medical, Inc. 10-Q 11/08/2017"General and Administrative                             (  Three Months Ended September 30, ' Nine Months Ended September 30, ~  ~  ~  ~ " General and administrative~ .  ~ 6 % ~ y  ~ " % ~   ~ . % ~ :|  ~ & % $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/(/T{ocW0=PF0*8X> @j            l  ?  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NxStage Medical Inc Balance SheetBalance Sheet (1)Income Statement Cash FlowsWarranty Costs!Recent Accounting PronouncementRecent Accounting (1)!7 Accrued Expenses Other Curren7 Accrued Expenses Other (1)7 Accrued Expenses Other (2)9 Segment Disclosures9 Segment Discl (1)!Stockbased Compensation Expense14 Noncontrolling Interest!15 Derivative Instruments and H!16 Accumulated Other Comprehens17 Fair Value Measurements17 Fair Value M (1)!18 Supplemental Cash Flow InforFinancial Performance RevenuesGross Profit LossSelling and MarketingResearch and Development DistributionGeneral and AdministrativeItem 6 ExhibitsU } 1} $      NxStage Medical, Inc. 10-Q 11/08/2017'Liquidity and Capital Resources         ' Nine Months Ended September 30, ~  ~ 1 )Net cash provided by operating activities~   ~ N . &Net cash used in investing activities~ ja  ~ ΍ 1)Net cash provided by financing activities~ ~ 60(Foreign exchange effect on cash and cash~ ~  equivalents Net cash flow~ N4~ b$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/2.vj^R+G;/=PF0*8X> @        l  4iS  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??NxStage Medical Inc Balance SheetBalance Sheet (1)Income Statement Cash FlowsWarranty Costs!Recent Accounting PronouncementRecent Accounting (1)!7 Accrued Expenses Other Curren7 Accrued Expenses Other (1)7 Accrued Expenses Other (2)9 Segment Disclosures9 Segment Discl (1)!Stockbased Compensation Expense14 Noncontrolling Interest!15 Derivative Instruments and H!16 Accumulated Other Comprehens17 Fair Value Measurements17 Fair Value M (1)!18 Supplemental Cash Flow InforFinancial Performance RevenuesGross Profit LossSelling and MarketingResearch and Development DistributionGeneral and Administrative!Liquidity and Capital ResourcesU } y } $ } > 4     NxStage Medical, Inc. 10-Q 11/08/2017Item 6. Exhibits    Exhibit   Description Number    31.1* 0 (Certification of Chief Executive Officer0(pursuant to Exchange Act Rules 13a-14(a)80or 15d-14(a), as adopted pursuant to Section 302&of Sarbanes-Oxley Act of 2002. 31.2*0(Certification of Chief Financial Officer0(pursuant to Exchange Act Rules 13a-14(a)80or 15d-14(a), as adopted pursuant to Section 302&of Sarbanes-Oxley Act of 2002.32.1**0(Certification of Chief Executive Officer0(pursuant to Exchange Act Rules 13a-14(b)0(or 15d-14(b) and 18 U.S.C. Section 1350,<4as adopted pursuant to Section 906 of Sarbanes-Oxley Act of 2002.32.2**0(Certification of Chief Financial Officer0(pursuant to Exchange Act Rules 13a-14(b)0(or 15d-14(b) and 18 U.S.C. Section 1350,Dlyma=4z)G#9; !"#$%&'()*+,-./0123  < 4as adopted pursuant to Section 906 of Sarbanes-Oxley!!! Act of 2002."""#101.INS*##XBRL Instance Document$$$%101.SCH*%&%XBRL Taxonomy Extension Schema&&&'101.CAL*'4',XBRL Taxonomy Extension Calculation Linkbase((()101.DEF*)3)+XBRL Taxonomy Extension Definition Linkbase***+101.LAB*+.+&XBRL Taxonomy Extension Label Linkbase,,,-101.PRE*-,-$XBRL Taxonomy Extension Presentation...Linkbase/0$1____________________________12)Created by Morningstar Document Research.03(http://documentresearch.morningstar.com/,|xT(7W=PF0*8X> @332211 Root Entry FBook    !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~